Drugs Containing Excipient (Inactive Ingredient) OLEYL ALCOHOL

« Back to Dashboard

Branded drugs containing OLEYL ALCOHOL excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Allergan Inc	RHOFADE	oxymetazoline hydrochloride	0023-5300	OLEYL ALCOHOL
Novartis Pharmaceuticals Corporation	VIVELLE-DOT	estradiol	0078-0365	OLEYL ALCOHOL
Bausch Health US LLC	ELIDEL	pimecrolimus	0187-5102	OLEYL ALCOHOL
Upsher-Smith Laboratories LLC	VOGELXO	testosterone	0245-0871	OLEYL ALCOHOL

Generic drugs containing OLEYL ALCOHOL excipient

Company	Ingredient	NDC	Excipient
Allergan Inc	oxymetazoline hydrochloride	0023-5300	OLEYL ALCOHOL
Novartis Pharmaceuticals Corporation	estradiol	0078-0365	OLEYL ALCOHOL
Bausch Health US LLC	pimecrolimus	0187-5102	OLEYL ALCOHOL
Upsher-Smith Laboratories LLC	testosterone	0245-0871	OLEYL ALCOHOL

Oleyl Alcohol Pharmaceutical Excipient Market Dynamics and Financial Trajectory

Last updated: October 28, 2026

Oleyl alcohol is a specialty fatty alcohol used primarily as an emollient, co-emulsifier, solvent, penetration-enhancing vehicle, and texture modifier in topical pharmaceutical products. Its pharmaceutical market is small relative to its cosmetic, personal-care, and industrial markets. Public companies generally do not report oleyl alcohol revenue separately, so a standalone global market size or company revenue forecast cannot be validated from public filings. The financial trajectory is best assessed through demand in topical dosage forms, oleochemical feedstock costs, regulatory requirements, and supplier concentration.

What is oleyl alcohol and how is it used in pharmaceutical formulations?

Oleyl alcohol, also known as 9-octadecen-1-ol, is an unsaturated C18 fatty alcohol with CAS Registry Number 143-28-2. It is usually supplied as a liquid or semi-liquid material with a characteristic fatty odor and a defined range of oleyl alcohol, related fatty alcohols, and unsaturated components.

In pharmaceutical formulations, oleyl alcohol is used for several technical functions:

Function	Formulation role	Typical dosage-form relevance
Emollient	Softens and conditions skin	Creams, ointments, lotions
Co-emulsifier	Supports oil-in-water or water-in-oil systems	Topical emulsions
Solvent or carrier	Helps dissolve lipophilic active ingredients	Semisolids and topical liquids
Penetration modifier	Changes drug partitioning into the stratum corneum	Transdermal and topical products
Texture modifier	Controls spreadability and skin feel	Dermatological products
Lubricity agent	Reduces drag during application	Creams, gels, and ointments

The strongest pharmaceutical demand is in topical and dermatological formulations. Oral use is less commercially important because oleyl alcohol has limited relevance as a conventional tablet excipient and is more valuable in systems requiring lipophilic compatibility or skin delivery.

The U.S. Food and Drug Administration’s Inactive Ingredient Database is the principal regulatory reference for whether an excipient has prior use in approved drug products and at what route and dosage-form levels. The database should be reviewed by route, dosage form, and maximum potency because an excipient’s presence in one topical product does not automatically support unrestricted use in all formulations.[1]

How large is the oleyl alcohol pharmaceutical excipient market?

No authoritative public source reports a separately audited global market value for pharmaceutical-grade oleyl alcohol. Market research reports commonly group the material with fatty alcohols, oleochemicals, emollients, specialty excipients, or personal-care ingredients. Those categories are too broad to produce a reliable pharmaceutical-only figure.

The commercial market has three major demand pools:

1. Personal care and cosmetics, which likely represent the largest volume.
2. Industrial applications, including lubricants, surfactants, and specialty chemicals.
3. Pharmaceutical formulations, which represent a smaller but higher-value segment because of documentation, quality controls, and batch traceability.

Pharmaceutical-grade material commands a premium over technical or cosmetic grades when the buyer requires:

• Controlled impurity profiles
• Lot-to-lot consistency
• Microbiological specifications
• Residual solvent controls
• Elemental impurity data
• Change-control commitments
• Auditable manufacturing records
• Regulatory support for abbreviated and full marketing applications

The pharmaceutical segment therefore contributes more value per kilogram than its volume share suggests. It remains too small for most producers to disclose as a separate reporting line.

What is the financial trajectory for oleyl alcohol?

The financial trajectory is linked more closely to oleochemical cycles than to pharmaceutical prescription growth. Oleyl alcohol producers are exposed to the cost and availability of feedstocks such as palm-derived fatty acids, palm kernel fractions, tallow, and other natural oils. Energy prices, hydrogen costs, freight rates, currency movements, and regional capacity also influence margins.

Financial driver	Directional effect on oleyl alcohol economics
Palm and tallow prices	Direct effect on raw-material cost
Hydrogen and energy prices	Affects hydrogenation and refining costs
Feedstock purity	Higher-purity inputs increase production cost
Freight and container availability	Raises landed cost for imported material
Pharmaceutical qualification	Increases price and switching barriers
Personal-care demand	Supports volume utilization
Industrial-cycle weakness	Can reduce producer operating rates
Regulatory documentation	Adds cost but supports premium pricing

Oleyl alcohol pricing is likely to remain cyclical rather than follow a smooth pharmaceutical-growth curve. When personal-care and industrial demand weaken, pharmaceutical demand can provide stable baseline volume but is unlikely to absorb enough material to offset a major reduction in broader oleochemical demand.

The medium-term financial profile is therefore characterized by:

• Low-to-moderate volume growth in pharmaceuticals
• Higher value per kilogram for qualified material
• Margin sensitivity to feedstock and energy costs
• Limited pricing power for undifferentiated grades
• Stronger pricing power for validated, compendial, or customer-qualified supply
• Potential margin expansion when producers sell into regulated applications rather than commodity channels

Which companies manufacture or supply pharmaceutical-grade oleyl alcohol?

The supply base is fragmented across large oleochemical groups, specialty chemical companies, and regional distributors. Relevant producer and supplier categories include:

• Integrated oleochemical manufacturers
• Fatty alcohol producers
• Specialty excipient distributors
• Cosmetic-ingredient suppliers with pharmaceutical documentation
• Custom manufacturers producing to customer specifications

Companies active in adjacent fatty alcohol and oleochemical markets include KLK OLEO, Wilmar International, Emery Oleochemicals, Sasol, and other regional producers. Their public reports generally discuss fatty alcohols, oleochemicals, surfactants, or care chemicals as business segments rather than identifying oleyl alcohol revenue separately.[2-5]

Supplier selection depends on more than nominal purity. Pharmaceutical buyers normally evaluate:

• Source of raw materials
• Animal-origin status
• Geographic manufacturing location
• Residual pesticides and contaminants
• Oxidative stability
• Peroxide and acid values
• Iodine value
• Water content
• Color and odor
• Packaging compatibility
• Supply continuity and dual sourcing
• Change-notification procedures

A supplier with a technically acceptable assay may still fail qualification if it cannot support regulatory filings, provide consistent impurity data, or maintain supply through feedstock disruptions.

What FDA regulatory status applies to oleyl alcohol?

Oleyl alcohol is regulated as an excipient when used in a drug product. It is not an active pharmaceutical ingredient and does not receive independent FDA approval as a standalone therapeutic product.

The principal FDA considerations are:

• Listing in the Inactive Ingredient Database
• Precedent for the proposed route and dosage form
• Quality specifications
• Manufacturing controls
• Toxicological justification where exposure exceeds established precedent
• Compatibility with the active ingredient and container-closure system
• Stability and degradation data

For a new drug application, the sponsor must establish that the excipient is suitable for the intended use. For an abbreviated new drug application, prior use in an approved product can reduce regulatory uncertainty, but the proposed concentration, route, and dosage form remain material.

FDA excipient review is product-specific. An IID entry does not create a broad authorization for every use. Sponsors must compare the proposed maximum daily exposure or topical concentration with the relevant database precedent and provide justification where the proposed use exceeds it.[1]

What pharmacopeial and international standards apply?

Oleyl alcohol may be purchased under a pharmaceutical specification, a compendial specification where available, or a customer-specific monograph. Buyers should distinguish among:

• USP-NF or other recognized compendial compliance
• Pharmaceutical grade
• Cosmetic grade
• Technical grade
• Internal supplier specification

These classifications are not interchangeable. A material labeled “high purity” may not satisfy the analytical, documentation, or change-control standards required for pharmaceutical manufacturing.

International regulatory review can involve:

• ICH Q3C residual solvents
• ICH Q3D elemental impurities
• ICH Q6A specification principles
• ICH Q9 quality-risk management
• EU excipient guidance and pharmaceutical-quality requirements
• National pharmacopoeial expectations
• Animal-origin and transmissible-spongiform-encephalopathy controls

The European Medicines Agency expects excipient risk assessment in marketing-authorization applications, including consideration of quality, safety, and function in the finished product.[6]

What formulations are protected by oleyl alcohol?

Oleyl alcohol itself generally does not provide a broad, durable patent barrier in pharmaceutical products. It is a known chemical with long-standing use in topical, cosmetic, and industrial formulations.

Potentially protectable subject matter may include:

• A specific composition containing oleyl alcohol and an active ingredient
• A narrow concentration range
• A particular emulsion or gel architecture
• A penetration-enhancing system
• A controlled-release topical formulation
• A combination of oleyl alcohol with surfactants, lipids, polymers, or solvents
• A manufacturing process that improves stability or bioavailability
• A method of treating a disease using a formulation containing oleyl alcohol

The commercial strength of these patents depends on claim scope, clinical or performance data, prosecution history, and design-around options. A formulation patent that claims only the presence of oleyl alcohol may be weak if the ingredient is conventional and the combination is obvious. Stronger claims typically require demonstrated pharmacokinetic, dermatological, stability, or manufacturing advantages.

How strong is the patent estate for oleyl alcohol?

The patent estate is best characterized as application-specific rather than molecule-specific. Oleyl alcohol is unlikely to support meaningful composition-of-matter exclusivity for pharmaceutical use. Patent value is concentrated in finished-product formulations and delivery systems.

IP category	Expected relevance
Composition of matter	Low for oleyl alcohol itself
Formulation patents	Moderate to high where performance data support narrow claims
Method-of-use patents	Variable and dependent on clinical differentiation
Manufacturing patents	Moderate where purification or oxidation control is difficult
Supplier process know-how	Potentially important but generally confidential
Trade secrets	Relevant for specifications, purification, and blending
Regulatory exclusivity	Applies to the drug product, not the excipient

Patent searches should use CAS 143-28-2, “oleyl alcohol,” “9-octadecen-1-ol,” formulation claims, topical delivery, transdermal delivery, emulsions, and relevant active ingredients. Patent expiration cannot be assigned reliably without identifying a specific drug product or patent family.

Are Paragraph IV challenges and generic risks relevant?

Oleyl alcohol does not face Paragraph IV litigation as an excipient by itself. Paragraph IV risk arises when a generic applicant challenges patents listed for an approved drug product that uses oleyl alcohol in its formulation.

The relevant questions are:

• Is the drug product listed in the FDA Orange Book?
• Are formulation or method-of-use patents listed?
• Does the generic use the same excipient?
• Can the generic design around oleyl alcohol?
• Does the patent claim require oleyl alcohol or only a functional formulation property?
• Is the product eligible for a 30-month stay following a Paragraph IV notice?

The Orange Book lists approved drug products and certain associated patents, but it does not create an independent patent register for excipients.[7] A generic applicant may use a different emollient or penetration enhancer if the alternative satisfies bioequivalence, pharmaceutical equivalence, and product-performance requirements.

What manufacturing and supply barriers affect the market?

The principal barrier is not chemical synthesis. It is consistent production of a narrowly specified, oxidation-sensitive fatty alcohol at pharmaceutical quality.

Key manufacturing risks include:

• Variation in chain-length distribution
• Isomer and positional-unsaturation differences
• Oxidation and peroxide formation
• Color and odor drift
• Residual catalyst or solvent
• Feedstock contamination
• Animal-origin concerns
• Seasonal feedstock availability
• Limited qualified production sites

Natural-origin oleyl alcohol can carry greater feedstock variability than a fully synthetic material. The producer must control refining, distillation, hydrogenation or related processing steps, storage conditions, and packaging. Nitrogen blanketing, antioxidant strategy, temperature control, and container compatibility can affect shelf life.

Qualification creates switching costs. A pharmaceutical manufacturer may need to repeat formulation, stability, extractables and leachables, process validation, and regulatory assessments after changing supplier or grade.

How does oleyl alcohol compare with alternative excipients?

Oleyl alcohol competes with other lipophilic excipients rather than with a single direct substitute.

Alternative	Relative advantage	Relative limitation
Oleic acid	Strong penetration and lipid compatibility	More acidic and potentially more irritating
Isopropyl myristate	Good spreadability and emollience	Different penetration and sensory profile
Stearyl alcohol	Stronger structuring and wax-like behavior	Less fluid and less unsaturated
Cetyl alcohol	Common co-emulsifier and thickener	Lower penetration-modifying potential
Oleyl oleate	High emollience and slip	May require different formulation architecture
Mineral oil	Stable and widely available	Less functional as a penetration modifier
Medium-chain triglycerides	Good solvent and emollient profile	Different viscosity and skin-feel characteristics

Oleyl alcohol is most competitive when a formulator requires a liquid fatty alcohol with both emollient and formulation-functional properties. It is less attractive when the principal requirement is low cost, oxidative stability, or high structural viscosity.

What licensing deals and litigation affect oleyl alcohol?

Publicly disclosed licensing deals specifically covering oleyl alcohol as a pharmaceutical excipient are not a material feature of the market. Commercial arrangements are more likely to involve:

• Supply agreements
• Preferred-vendor contracts
• Private-label manufacturing
• Regional distribution rights
• Formulation licenses involving a finished drug
• Confidential quality agreements

Litigation risk is normally associated with the finished formulation, manufacturing contract, product liability, or supply interruption rather than ownership of oleyl alcohol itself. A supplier dispute can still have regulatory consequences if the replacement grade changes impurity levels, stability, or product performance.

What is the outlook for pharmaceutical oleyl alcohol demand?

The outlook is stable but niche. Demand should benefit from continued development of topical and dermatological products, including:

• Prescription creams and ointments
• Over-the-counter skin treatments
• Transdermal delivery systems
• Barrier-repair products
• Dermatology generics
• Combination topical products
• Specialty cosmetic-pharmaceutical products

Growth will be constrained by substitution, the small number of high-volume pharmaceutical products using the material, and the availability of alternative emollients. Revenue growth is more likely to come from specification upgrades, supplier qualification, and higher-value pharmaceutical grades than from large increases in physical volume.

Key Takeaways

• Oleyl alcohol is a specialty C18 fatty alcohol used mainly in topical and dermatological formulations.
• The pharmaceutical market is smaller than the personal-care and industrial markets.
• No reliable public source reports standalone global pharmaceutical oleyl alcohol revenue.
• Financial performance is driven by oleochemical feedstock prices, energy, freight, and pharmaceutical-grade premiums.
• The molecule itself has limited patent value; commercial protection is concentrated in finished formulations and delivery systems.
• FDA status depends on route, dosage form, concentration, and prior IID precedent.
• Paragraph IV risk applies to drug products that use oleyl alcohol, not to the excipient independently.
• Supply qualification, oxidation control, impurity management, and change control are the main manufacturing barriers.
• Near-term demand is likely to be stable to moderately growing, with value growth exceeding volume growth in qualified pharmaceutical grades.

FAQs

Is oleyl alcohol a pharmaceutical excipient?

Yes. Oleyl alcohol is used as an inactive ingredient, especially in topical and dermatological formulations, subject to product-specific regulatory review and appropriate quality specifications.

What is the CAS number for oleyl alcohol?

The CAS Registry Number is 143-28-2. The chemical name is 9-octadecen-1-ol.

Is oleyl alcohol listed in the FDA Inactive Ingredient Database?

Oleyl alcohol has FDA inactive-ingredient precedent, but sponsors must verify the current entry, route, dosage form, and maximum potency in the FDA database before relying on it for a specific product.[1]

Does oleyl alcohol have drug patent protection?

Oleyl alcohol itself generally does not have meaningful pharmaceutical composition-of-matter protection. Patent protection may apply to a particular drug formulation, delivery system, manufacturing method, or therapeutic use containing the excipient.

Can a generic drug replace oleyl alcohol with another excipient?

Potentially. The substitute must support pharmaceutical equivalence, bioequivalence or equivalent product performance, stability, manufacturing validation, and regulatory approval. The feasibility depends on the drug product and the claims of any listed patents.

References

1. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm
2. KLK OLEO. (2024). Annual report and oleochemical product information. https://www.klkoleo.com/
3. Wilmar International Limited. (2024). Annual report. https://www.wilmar-international.com/
4. Sasol Limited. (2024). Integrated report. https://www.sasol.com/
5. Emery Oleochemicals. (n.d.). Oleochemicals and specialty chemicals product information. https://www.emeryoleo.com/
6. European Medicines Agency. (2015). Guideline on the assessment of the quality of medicinal products containing chemical entities. https://www.ema.europa.eu/
7. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book